UNIQA Insurance Group AG AI Price Prediction

With EPS of €1.18 and a PE ratio of 13.02, UNIQA appears reasonably valued for a European insurer, suggesting neither clear undervaluation nor overvaluation based solely on earnings. Profitability looks adequate but not exceptional, and without multi‑year revenue and margin data, the picture is broadly stable rather than strongly improving.

• EPS of €1.18 combined with a share price of €15.36 implies a PE of 13.02, in line with many traditional European insurers and consistent with moderate, not high‑growth expectations.
• The valuation multiple suggests the market sees UNIQA as a steady, income‑oriented insurer rather than a high‑beta growth story, pointing to balanced risk‑reward.
• Lack of detailed recent revenue and margin trends limits conviction; available figures imply solid but unspectacular profitability, leading to a broadly neutral stance on fundamentals.

Alternative data for UNIQA is mixed but broadly stable: web traffic is flat, app downloads are robust, and hiring and social media metrics show only modest changes. These signals point to a steady business presence and customer engagement rather than a clear acceleration or deterioration.

• Website traffic at an estimated 29,328 visitors per month with 0.0% month‑over‑month growth suggests stable but not rapidly expanding digital interest.
• Estimated 7,000 mobile app downloads per day indicate strong ongoing customer acquisition or engagement through digital channels, a constructive sign for an insurer’s distribution and retention.
• Job openings at 59, down 4.8% month over month, and largely flat social media follower trends (small gains on Instagram and Facebook, slight declines on Twitter/X and TikTok) imply a steady, mature franchise rather than aggressive expansion or contraction.

UNIQA Insurance Group AG shows solid technical strength with the share price well above its 200‑day moving average and a positive recent return, but fundamentals and alternative data look broadly stable rather than strongly improving. Overall, the setup appears balanced: constructive price action tempered by only moderate evidence of accelerating growth or demand.

• Bullish technicals (price above 200‑day MA and RSI in a strong but not extreme zone) support a positive near‑term outlook, though with some risk of overextension.
• Fundamentals and alternative data currently point to a steady, mature insurer rather than a clear growth inflection, leading to an overall neutral stance on the stock’s risk‑reward profile at current levels.